Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity

Cancer Biology and Therapy

Volumn 17, Issue 12, 2016, Pages 1231-1239

  Li, Jing ^a   Zhou, Changhua ^a   Dong, Bin ^a   Zhong, Hong ^a   Chen, Siqi ^a   Li, Qing ^a   Wang, Zhong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bispecific antibody; CD16; CEA; single domain antibody; SS Fc

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC SS FC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD16 ANTIGEN; IMMUNOGLOBULIN FC FRAGMENT; NANOBODY; UNCLASSIFIED DRUG; FC RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PLASMID; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR XENOGRAFT; ANIMAL; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; HT-29 CELL LINE; HUMAN; IMMUNOGLOBULIN DOMAIN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; DRUG DESIGN; HT29 CELLS; HUMANS; IMMUNOGLOBULIN DOMAINS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; RECEPTORS, IGG; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84997795126     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1235659     Document Type: Article

References (31)

1. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities:bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
2. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol 2012; 12:709-19; PMID:23007571; http://dx.doi.org/10.1038/nri3285
3. Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
4. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H. Protein engineering of single-chain Fv analogs and fusion proteins. Method Enzymol 1991; 203:46-88; PMID:1762568; http://dx.doi.org/10.1016/0076-6879(91)03005-2
5. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs:bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44; PMID:16213416; http://dx.doi.org/10.1016/S1359-6446(05)03554-3
6. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545
7. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
8. Nguyen VK, Su C, Muyldermans S, van der Loo W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics 2002; 54:39-47; PMID:11976790; http://dx.doi.org/10.1007/s00251-002-0433-0
9. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
10. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
11. Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugniere M, Teillaud J-L, Gruaz-Guyon A, Pelegrin A, Baty D. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 2009; 276:3881-93; PMID:19531051; http://dx.doi.org/10.1111/j.1742-4658.2009.07101.x
12. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, Sautes-Fridman C, Teillaud JL, Baty D. Isolation and characterization of anti-Fc gamma RIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008; 21:1-10; PMID:18073223; http://dx.doi.org/10.1093/protein/gzm064
13. Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pelegrin A, Chames P, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther 2013; 12:1481-91; PMID:23757164; http://dx.doi.org/10.1158/1535-7163.MCT-12-1012
14. Pavoni E, Flego M, Dupuis ML, Barca S, Petronzelli F, Anastasi AM, D'Alessio V, Pelliccia A, Vaccaro P, Monteriu G, et al. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. BMC Cancer 2006; 6:41; PMID:16504122; http://dx.doi.org/10.1186/1471-2407-6-41
15. Hong H, Sun J, Cai W. Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen. Biomark Insights 2008; 3:435-51; PMID:19578524
16. Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E, Jorieux S, Fridman WH, Teillaud JL. Molecular aspects of human FcgammaR interactions with IgG:functional and therapeutic consequences. Immunol Lett 2006; 106:111-8; PMID:16797726; http://dx.doi.org/10.1016/j.imlet.2006.05.009
17. Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014; 6:1571-84; PMID:25484061; http://dx.doi.org/10.4161/19420862.2014.975660
18. Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010; 12:176-83; PMID:20373261
19. Sanford M. Blinatumomab:first global approval. Drugs 2015; 75:321-7; PMID:25637301; http://dx.doi.org/10.1007/s40265-015-0356-3
20. Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, Eigenbrot C, Scheer JM. Antiparallel Conformation of Knob and Hole Aglycosylated Half-Antibody Homodimers Is Mediated by a CH2-CH3 Hydrophobic Interaction. J Mol Biol 2014; 426:1947-57; PMID:24576605; http://dx.doi.org/10.1016/j.jmb.2014.02.015
21. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects:applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
22. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies:fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
23. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
24. Stein R, Goldenberg DM. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004; 3:1559-64; PMID:15634649
25. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 2010; 107:604-9; PMID:20080725; http://dx.doi.org/10.1073/pnas.0908590107
26. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
27. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
28. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LGJ, Muyldermans S, Wyns L, Matagne A. Single-domain antibody fragments with high conformational stability. Protein Sci 2002; 11:500-515; PMID:11847273; http://dx.doi.org/10.1110/ps.34602
29. Su C, Nguyen VK, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. Mol Biol Evolut 2002; 19:205-15; PMID:11861879; http://dx.doi.org/10.1093/oxfordjournals.molbev.a004073
30. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009; 284:3273-84; PMID:19010777; http://dx.doi.org/10.1074/jbc.M806889200
31. Spiess C, Merchant M, Huang A, Zheng Z, Yang N-Y, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, Scheer JM. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621